Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1055437 | 0.90 | POLB (0.43) | ALDH1A1MEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL1055316 | 0.89 | CYP2C9 (0.44) | ALDH1A1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL1051730 | 0.86 | CYP3A4 (0.46) | ALDH1A1KMT2AKDM4EPOLBCYP3A4 | |
| SCHEMBL1055189 | 0.82 | GAA (0.43) | MEN1KMT2AGAANPSR1CYP3A4 | |
| SCHEMBL1055173 | 0.82 | GRM5 (0.44) | ALDH1A1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL1053092 | 0.76 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL13450498 | 0.74 | POLB (0.43) | ALDH1A1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL1051423 | 0.72 | LIMK2 (0.52) | ALDH1A1MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL1053241 | 0.72 | GLA (0.48) | ALDH1A1MEN1KMT2AKDM4EHPGD | |
| SCHEMBL13162702 | 0.71 | ALDH1A1 (0.51) | ALDH1A1KMT2AKDM4EHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868026-B2 | Therapeutic compounds | PFIZER INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868026-B2 | Therapeutic compounds | PFIZER INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868026-B2 | Therapeutic compounds | PFIZER INC. (US) | 2011-01-11 | — | — | US | disclosed |
| EP-1937639-B1 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-1937639-B1 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-20070167497-A1 | Therapeutic Compounds | PFIZER INC | 2007-07-19 | — | — | US | disclosed |
| US-20070167497-A1 | Therapeutic Compounds | PFIZER INC | 2007-07-19 | — | — | US | disclosed |
| US-20070167497-A1 | Therapeutic Compounds | PFIZER INC | 2007-07-19 | — | — | US | disclosed |
| WO-2007034312-A2 | PYRIDINAMINOSULFONYL SUBSTITUTED BENZAMIDES AS INHIBITORS OF CYTOCHROME P450 3A4 (CYP3A4) | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167497-A1 | Therapeutic Compounds | SLC10A1, PCSK9, CFTR | ALDH1A1 310/4885MEN1 1198/4885KMT2A 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.